Rituxan associated with PML, warns US FDA

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1569, 2007-01, pp. : 21-21

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rituxan associated with PML, warns US FDA

By  

Reactions Weekly, Vol. 1, Iss. 1133, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

US FDA warns of increased myopathy risk with Zocor

By  

Reactions Weekly, Vol. 1, Iss. 1294, 2010-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

US FDA warns about ibuprofen and aspirin interaction

By  

Inpharma, Vol. 1, Iss. 1555, 2006-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

A possible fifth case of Tysabri [natalizumab]-associated progressive multifocal leukoencephalopathy (PML) has been reported to the US FDA.

By  

Reactions Weekly, Vol. 1, Iss. 1057, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Oral sodium phosphates: acute renal failure risk, warns US FDA

By  

Reactions Weekly, Vol. 1, Iss. 1101, 2006-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite